Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: The randomised phase I/II POSEIDON trial

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 132-140

  Elez E ^a   Kocakova I ^b   Hohler T ^c   Martens, U M ^d   Bokemeyer, C ^e   Van cutsem, E ^f   Melichar, B ^g   Smakal, M ^h   Csoszi, T ^h   Topuzov, E ⁱ   Orlova, R ^j   Tjulandin, S ^k   Rivera, F ^l   Straub, J ^m   Bruns, R ^m   Quaratino, S ^m   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c PROSPER HOSPITAL   (Germany)

^d Cancer Center Heilbronn Franken   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g PALACKÝ UNIVERSITY   (Czech Republic)

^h Department of Oncology ^*  (Hungary)

ⁱ N a Mechnikov Federal Agency of Healthcare   (Germany)

^j City Clinical Oncology Dispensary   (Germany)

^k N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^l HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^m MERCK KGAA   (Germany)

more..

Author keywords

Abituzumab; Biomarker; Colorectal cancer; Integrin; Monoclonal antibody; Phase I II

Indexed keywords

ABITUZUMAB; BETA6 INTEGRIN; CD51 ANTIGEN; CETUXIMAB; INTEGRIN; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DI17E6; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; COLITIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; EXON; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL INFECTION; HUMAN; HYPOKALEMIA; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; ONCOGENE K RAS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN ABSCESS; STOMATITIS; TACHYCARDIA; TREATMENT RESPONSE; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTEGRIN ALPHAV; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84922561479     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu474     Document Type: Article

References (17)

1. Van Cutsem E, Cervantes A, Nordlinger B et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(suppl 3): iii1-iii9.
2. Ciombor KK, Berlin J. Targeting metastatic colorectal cancer-present and emerging treatment options. Pharmgenomics Pers Med 2014; 7: 137-144.
3. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33: 405-412.
4. Nemeth JA, Nakada MT, Trikha M et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007; 25: 632-646.
5. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 2012; 1: 329-340.
6. Agrez MV, Bates RC, Mitchell D et al. Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer. Br J Cancer 1996; 73: 887-892.
7. Bates RC, Bellovin DI, Brown C et al. Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115: 339-347.
8. Mitjans F, Sander D, Adan J et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108(Pt 8): 2825-2838.
9. Uhl W, Zuhlsdorf M, Koernicke T et al. Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs 2014; 32: 347-354.
10. Wirth M, Heidenreich A, Gschwend JE et al. A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting alphav integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur Urol 2014; 65: 897-904.
11. Elez E, Kocáková I, Höhler T et al. Phase I study of EMD 525797 (DI17E6), an antibody targeting ανβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer. J Clin Oncol 2012; 30(suppl): abstract 3539.
12. Pirker R, Pereira JR, von Pawel J et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-smallcell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13: 33-42.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. In Committee for Medicinal Products for Human Use (ed), London, UK: European Medicines Agency 2013.
15. Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. In Services USDoHaH (ed), Rockville, MD, USA: Food and Drug Administration 2007.
16. Bates RC. Colorectal cancer progression: integrin alphavbeta6 and the epithelialmesenchymal transition (EMT). Cell Cycle 2005; 4: 1350-1352.
17. Travis MA, Sheppard D. TGF-beta activation and function in immunity. Annu Rev Immunol 2014; 32: 51-82.